Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults.
BACKGROUND
Current recommendations direct health care providers to administer smallpox vaccine to the upper outer arm. However, concerns about cosmetically bothersome scarring, accidental contact transmission, interference by body tattoos, and even malignant transformation suggest evaluation of alternate vaccination sites is warranted.


METHODS
We randomized 20 vaccinia-naive adults to undergo smallpox vaccination on the outer (n = 10) or inner (n = 10) upper arm. Evaluations included major reaction ("take") rates and vaccination site cultures on postvaccination day 7, determination of serum vaccinia-specific neutralizing antibody titers on days 0 (prevaccination) and 21, and determination of adverse events.


RESULTS
On postvaccination day 7, a total of 18 participants (9 per group) had major reactions, 17 of whom had culture evidence of viable vaccinia. The inner and outer arm groups had similar major reaction mean sizes (P = .17), but the amount of erythema (in square centimeters) was smaller in the inner arm group (P = .05). At day 21, all participants had higher titers of vaccinia-specific neutralizing antibodies, compared with at day 0, and the geometric mean titer values of the 2 vaccine groups were similar (P = .45). Adverse event rates were similar.


CONCLUSIONS
The comparable clinical, immunological, and tolerability outcomes between smallpox vaccine applied to the conventional upper outer arm site versus the upper inner arm, coupled with modestly less vaccine-site erythema on the inner arm, indicate that the inner arm may be a suitable alternate vaccination site.
Waibel
Kirk H
KH
Department of Medicine, Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA 30905-5650, USA. kirk.waibel@se.amedd.army.mil
Golding
Hana
H
Manischewitz
Jody
J
King
Lisa R
LR
Tuchscherer
Margaret
M
Topolski
Richard L
RL
Walsh
Douglas S
DS
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001132:Arm; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D016037:Single-Blind Method; D012899:Smallpox / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000008:administration & dosage*; D014615:Vaccinia / Q000097:blood* / Q000209:etiology; D012901:Variola virus / Q000276:immunology*
D000914:Antibodies, Viral; D012900:Smallpox Vaccine